NEW YORK, May 14, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), Athersys, Inc. (NASDAQ: ATHX), Nevro Corp. (NYSE: NVRO), Radius Health, Inc. (NASDAQ: RDUS), and OvaScience, Inc. (NASDAQ: OVAS). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
IDRA Research Report: ( http://get.analystsreview.com/pdf/?c=Idera%20Pharmaceuticals&d=14-May-2015&s=IDRA ),
ATHX Research Report: ( http://get.analystsreview.com/pdf/?c=Athersys&d=14-May-2015&s=ATHX ),
NVRO Research Report: ( http://get.analystsreview.com/pdf/?c=Nevro%20Corp&d=14-May-2015&s=NVRO ),
RDUS Research Report: ( http://get.analystsreview.com/pdf/?c=Radius%20Health&d=14-May-2015&s=RDUS ),
OVAS Research Report: ( http://get.analystsreview.com/pdf/?c=OvaScience&d=14-May-2015&s=OVAS ).
============
--
Analyst Update: Earnings Update, Regulatory Approval
U.S. stocks closed virtually flat on Wednesday, amid disappointing monthly retail sales data. The Dow Jones Industrial Average fell 0.04%, to finish at 18,060.49, the S&P 500 edged down 0.03%, to 2,098.48, while the NASDAQ Composite rose modestly by 0.11%, to end the session at 4,981.69. European stocks mostly closed lower on Wednesday, despite positive economic growth data. Germany's DAX 30 declined 1.05%, and France's CAC 40 slipped 0.26%. In contrast, London's FTSE 100 closed 0.23% higher on Wednesday, mainly reflecting upbeat unemployment data. Meanwhile, Asian markets were mixed on Wednesday, amid weaker Chinese economic data. The Shanghai Composite and Hong Kong's Hang Seng were both down on Wednesday, while Japan's Nikkei closed higher.
On May 11, 2015, Idera Pharmaceuticals, Inc. reported its financial and operational results for Q1 FY15. Revenue rose to $34,000 in Q1 FY15 from $3,000 in Q1 FY14. Net loss applicable to common stockholders for Q1 FY15 was $12.5 million, or $0.12 per diluted share, compared to $9.1 million, or $0.12 per diluted share, for the same period in 2014.
On May 11, 2015, Athersys, Inc. announced its Q1 FY15 results. Revenue rose by 3.4% to $0.73 million in Q1 FY15 from $0.71 million in Q1 FY14. R&D expenses were $5.7 million for the first quarter of 2015 compared to $6.2 million for the prior-year period.
On May 8, 2015, Nevro Corp., a medical device company that provides solutions for the treatment of chronic pain, announced that it has received approval from the United States Food and Drug Administration (FDA) for its Senza spinal cord stimulation (SCS) system.
On May 6, 2015, Radius Health, Inc. announced its Q1 FY15 results. Net loss for Q1 FY15 was $17.1 million, or $0.47 per share, as compared to a net loss of $14.5 million, or $50.45 per share for Q1 FY14.
OvaScience reported its Q1 FY15 financial results on May 11, 2015. Net loss for the quarter was $17.2 million, or $0.65 per share, as compared to net loss of $7.8 million, or $0.41 per share, for the same period in 2014.
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
